02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
17:37 , Mar 8, 2019 |  BC Week In Review  |  Company News

CARsgen's BCMA CAR T moving to clinic in China

CARsgen said CT053 (CAR-BCMA) received IND clearance from China's National Medical Products Administration (NMPA). CARsgen Therapeutics Co. Ltd. (Shanghai, China) said it is also planning to submit this year an IND to FDA for the...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
22:23 , Nov 1, 2018 |  BC Extra  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
19:45 , Sep 10, 2018 |  BC Extra  |  Clinical News

CARsgen solid tumor CAR T leads to complete response

CARsgen Therapeutics Co. Ltd. (Shanghai, China) said its CAR-CLD18 T cell therapy led to five objective responses, including one complete response, in a pilot trial to treat relapsed or refractory gastric or pancreatic cancer. The...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis...
18:13 , May 11, 2018 |  BC Week In Review  |  Financial News

ICT announces $28.3M series B round

Innovative Cellular Therapeutics Co. Ltd. (Shanghai, China) raised RMB180 million ($28.3 million) in a series B round led by Volcanic Ventures and GTJA Investment Group, with participation from SBCVC, Dunhou Capital and Witruth Capital. The...
21:04 , May 10, 2018 |  BC Extra  |  Financial News

Chinese companies MabSpace and ICT announce series B rounds

MabSpace Biosciences Co. Ltd. (Suzhou, China) and Innovative Cellular Therapeutics Co. Ltd. (Shanghai, China) raised $40 million and RMB180 million ($28.3 million), respectively, in series B rounds. New investor Sequoia Capital China led MabSpace’s round...